Your browser doesn't support javascript.
loading
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies.
Toma, Monika; Sullivan-Reed, Katherine; Sliwinski, Tomasz; Skorski, Tomasz.
Affiliation
  • Toma M; Sol Sherry Thrombosis Research Center and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA. monikatoma3@gmail.com.
  • Sullivan-Reed K; Laboratory of Medical Genetics Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland. monikatoma3@gmail.com.
  • Sliwinski T; Sol Sherry Thrombosis Research Center and Fels Institute for Cancer Research and Molecular Biology Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA. katherine.s.reed@temple.edu.
  • Skorski T; Laboratory of Medical Genetics Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland. tomasz.sliwinski@biol.uni.lodz.pl.
Cancers (Basel) ; 11(10)2019 Oct 14.
Article in En | MEDLINE | ID: mdl-31615159
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2019 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2019 Type: Article Affiliation country: United States